News

The company has posted a net loss of $14.23m for the second quarter 2010, or $0.21 per diluted share, compared to net loss of $13m, or $0.23 per

The results of a pre-specified analysis in patients treated in the second- and third-line setting showed an improvement in overall survival and progression-free survival. The overall safety analysis

The first Phase I clinical trial is a single-ascending dose study in 32 healthy volunteers, while the second trial is a multiple-ascending dose study in 32 RA patients

According to the company, the Berinert marketing approval is given on the basis of positive results from Phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial

NCPDP’s new product will give subscribers timely access to legislative intelligence, as well as customized reports to analyze and track key developments in pharmacy legislation. NCPDP’s customized State

UPEI and AVRF under the collaboration have formed a new compound resulting in the chemical combination of 2 distinct nutraceuticals. UPEI chairman Tarek Saleh said ongoing research suggests

In the notice, Rex has alleged that Angiotech materially breached its obligations under the agreement, and stated that the agreement will be terminated automatically on 24 April 2011.

Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs. QPS president

Net income was $377,000 for the first quarter 2010, or $0.02 loss per diluted share, compared to $1.92m, or $0.11 per diluted share, for the comparable period in